

**Final Agenda**  
**52<sup>nd</sup> meeting of the Committee for Risk Assessment**

**9 - 13 March 2020**  
**and**  
~~**17 - 20 March 2020**~~ **CANCELLED**

**ECHA Conference Centre (Telakkakatu 6, Helsinki)**

**Monday 9 March starts at 09.00**  
**Friday 13 March breaks at 13.00**  
~~**Tuesday 17 March resumes at 14.00**~~  
~~**Friday 20 March ends at 13.00**~~

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/52/2020***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

- a) Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

***For agreement***

## **Item 5 – Report from other ECHA bodies and activities**

- a) Report on RAC-51 action points, written procedures and update on other ECHA bodies

**RAC/52/2020/01**  
**Room document**  
**For information**

- b) RAC Work Plan for all processes

**For information**

## **Item 6 – Health based exposure limits at the workplace**

### **6.1 Health based exposure limits at the workplace**

- a) Opinion development
- 1) Diisocyanates – first draft opinion
  - 2) Lead and its compounds – first draft opinion

**For discussion**

## **Item 7 – Harmonised classification and labelling (CLH)**

### **7.1 CLH dossiers**

#### **~~A. Hazard classes for agreement without plenary debate (fast track)~~**

- Acetamiprid (ISO): acute toxicity (oral)
- Isoflucypram: physical hazards, acute toxicity, STOT SE, skin corrosion / irritation, serious eye damage / eye irritation, respiratory and skin sensitisation, germ cell mutagenicity, aspiration hazards, hazards to the aquatic environment
- Ammonium bromide: acute toxicity (dermal and oral), STOT SE, serious eye damage / eye irritation, skin corrosion / irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity
- Dimoxystrobin (ISO): acute toxicity, skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, hazards to the aquatic environment
- Cyfluthrin (ISO): physical hazards, acute toxicity (dermal), skin corrosion / irritation, serious eye damage / eye irritation
- Beta-cyfluthrin (ISO): physical hazards, acute toxicity (dermal), skin corrosion / irritation, serious eye damage / eye irritation
- 2,4,6-tri-tert-butylphenol: acute toxicity (oral, dermal), skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT SE
- Sodium pyrethrin: physical hazards, acute toxicity, skin corrosion/ irritation, serious eye damage / eye irritation, STOT SE, germ cell mutagenicity, carcinogenicity, hazards to the aquatic environment
- Pendimethalin (ISO): hazards to the aquatic environment

- Pyridalyl (ISO): physical hazards (except explosives and self-reactive substance), acute toxicity, skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, STOT RE, STOT SE, hazards to the aquatic environment

### **~~B. Hazard classes for agreement with plenary debate~~**

- ~~1) acetamiprid (ISO)~~
- ~~2) isoflucypram~~
- ~~3) ammonium bromide~~
- ~~4) dimoxystrobin (ISO)~~
- ~~5) cyfluthrin (ISO)~~
- ~~6) beta-cyfluthrin (ISO)~~
- ~~7) diethylene glycol monomethyl ether (2-(2-methoxyethoxy ethanol) (DEGME)~~
- ~~8) 2,4,6-tri-tert-butylphenol~~
- ~~9) sodium pyrithione~~
- ~~10) bisphenol A~~
- ~~11) pendimethalin (ISO)~~
- ~~12) pyridalyl (ISO)~~
- ~~13) methyl methacrylate~~

***For discussion and adoption***

## **Item 8 – Restrictions**

### **8.1 General restriction issues**

- a) Revised Working Procedure for opinion development

***RAC/52/2020/02***

***For information***

- b) Update from Restriction Task Force

***For information***

### **8.2 Restriction Annex XV dossiers**

- a) Conformity check
  - 1) Perfluorohexanoic acid (PFHxA)

***For discussion and agreement***

- b) Opinion development
  - 1) Calcium cyanamide in fertilisers – second draft opinion

***For discussion***

- 2) Formaldehyde and formaldehyde releasers – final draft opinion
- 3) Microplastics – sixth draft opinion / final draft opinion

- 4) Perfluorohexane-1-sulphonic acid, its salts and related substances – final draft opinion (PFHxS)
- 5) Skin sensitisers in textile – final draft opinion

***For discussion and adoption***

## **Item 9 – Authorisation**

### **9.1 General authorisation issues**

- a) Update on incoming/future applications
- b) Report from RAC WG on AfAs during February 2020 meeting

***For information/discussion***

### **9.2 Authorisation applications**

- a) Discussion on key issues
  - 1) 10 applications for authorisation from November 2020 submission window (OPE/NPE)

***For discussion***

- b) Agreement on draft opinions

#### **A. Hazard classes for agreement without plenary debate (A-list)**

- 1) 159\_OPE\_Merck (1 use)
- 2) 146\_CT\_TataSteel (1 use)
- 3) 179\_OPE\_Octapharma (Use 2 only)
- 4) 166\_OPE\_Ompi (1 use)
- 5) 177\_OPE\_Abbott\_2 (1 use)

#### **B. Hazard classes for agreement with plenary debate**

- 1) 151\_CTPht\_AO\_Rutgers (1 use)
- 2) 153\_CTPht\_AO\_Bilbaina (1 use)
- 3) 147\_CTPht\_Bilbaina (1 use)
- 4) 148\_CTPht\_DEZA (1 use)
- 5) 171\_OPE\_Wallac (2 uses)
- 6) 188\_OPE\_Wallac\_2 (1 use)
- 7) 179\_OPE\_Octapharma (Use 1 only)
- 8) 157\_OPE\_Kedrion (1 use)
- 9) 168\_OPE\_Vetter (1 use)
- 10) 169\_OPE\_Nordisk (1 use)
- 11) 167\_OPE\_Roche (1 use)
- 12) 158\_OPE\_Sanofi (1 use)
- 13) 161\_OPE\_Swords (1 use)
- 14) 173\_OPE\_Sobi (1 use)
- 15) 155\_OPE\_Siemens\_2 (5 uses)
- 16) 175\_OPE\_Rousselot (1 use)
- 17) 174\_OPE\_Eli\_Lilly (1 use)
- 18) 183\_NPE\_GEHC\_Bio-Sciences (1 use)
- 19) 176\_OPE\_Abbott\_1 (5 uses)
- 20) 181\_OPE\_NPE\_Roche (3 uses)

***For discussion and agreement***

- c) Adoption on opinions
  - 1) 135\_CT\_TES (1 use)
  - 2) 138\_OPE\_Boehringer (1 use)

***For discussion and adoption***

- d) Status update
  - 1) 149\_CTPht\_Nalon (1 use)
  - 2) 150\_CTPht\_AO\_Koppers (1 use)
  - 3) 152\_CTPht\_AO\_RainCarbon (1 use)

***For information***

**Item 10 – AOB**

**Item 11 – Minutes of RAC-52**

Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-52

***For adoption***

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-52 – WEEK 1**

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

### **Monday 9 March 2020: Morning session**

- Item 1 – Welcome and Apologies
- Item 2 – Adoption of the Agenda
- Item 3 – Declarations of conflicts of interest to the Agenda
- Item 5 – RAC Work Plan for Restriction, Authorisation and C&L processes
- Item 8 – Restrictions

### **Monday 9 March 2020: Afternoon session**

- Item 8 – Restrictions

### **Tuesday 10 March 2020: Morning session**

- Item 6 – Health based exposure limits at the workplace

### **Tuesday 10 March 2020: Afternoon session**

- Item 6 – Health based exposure limits at the workplace
- Item 8 – Restrictions

### **Wednesday 11 March 2020: Morning session**

- Item 8 – Restrictions

### **Wednesday 11 March 2020: Afternoon session**

- Item 8 – Restrictions

### **Thursday 12 March 2020: Morning session**

- Item 8 – Restrictions
- Item 9 – Authorisation applications

### **Thursday 12 March 2020: Afternoon session**

- Item 9 – Authorisation applications

### **Friday 13 March 2020: Morning session**

- Item 9 – Authorisation applications
- Item 11 – Minutes of RAC-52